Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
暂无分享,去创建一个
Scott E. Smith | Allison M. Booth | J. Byrd | R. Larson | N. Heerema | S. Mandrekar | G. Lozanski | R. Stone | J. Blachly | A. Ruppert | Jennifer R. Brown | N. Bartlett | Weiqiang Zhao | D. Brander | K. Rogers | H. Ozer | S. Coutre | J. Abramson | B. Fruth | H. Erba | M. Litzow | A. Hurria | C. Owen | R. Little | S. Parikh | P. Barr | J. Woyach | S. Nattam | W. Ding | C. Kuzma | Brittny T Major-Elechi
[1] J. Byrd,et al. Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies. , 2018, Journal of the American College of Cardiology.
[2] T. Kipps,et al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 , 2018, Haematologica.
[3] Jeffrey A Jones,et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. , 2018, Blood.
[4] Marco Montillo,et al. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia , 2018, The New England journal of medicine.
[5] Jeffrey A Jones,et al. Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia , 2017 .
[6] J. Healey,et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. , 2016, Blood.
[7] W. Klapper,et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. , 2016, The Lancet. Oncology.
[8] Jeffrey A Jones,et al. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.
[9] T. Kipps,et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. , 2015, The New England journal of medicine.
[10] A. Roberts,et al. The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial , 2015 .
[11] S. Pittaluga,et al. Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. , 2014, Blood.
[12] Jeffrey A Jones,et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. , 2014, Blood.
[13] Michael Hallek,et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. , 2014, The New England journal of medicine.
[14] Lisa L. Smith,et al. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). , 2014, Blood.
[15] A. Langerak,et al. Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. , 2013, American journal of blood research.
[16] Guido Marcucci,et al. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] C. Geest,et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. , 2012, Blood.
[18] N. Chiorazzi,et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. , 2012, Blood.
[19] Jeffrey A Jones,et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. , 2011, Blood.
[20] A. Berrebi,et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.
[21] ONSTANZE,et al. GENOMIC ABERRATIONS AND SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA , 2010 .
[22] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[23] T. Haferlach,et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping , 2007, Leukemia.
[24] R. Hendriks,et al. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. , 2007, Immunity.
[25] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.